1 / 64

NICOTINE REPLACEMENT THERAPY IN SMOKING CESSATION

NICOTINE REPLACEMENT THERAPY IN SMOKING CESSATION. SCOTT SLEDGE, MD FEBRUARY 2, 1999. CIGARETTE SMOKING RELATED MORTALITY. Cigarette Smoking is the single most preventable cause of premature death in the United States. >400,000 deaths in the U.S. / year

aelan
Download Presentation

NICOTINE REPLACEMENT THERAPY IN SMOKING CESSATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NICOTINE REPLACEMENT THERAPY INSMOKING CESSATION SCOTT SLEDGE, MD FEBRUARY 2, 1999

  2. CIGARETTE SMOKING RELATED MORTALITY • Cigarette Smoking is the single most preventable cause of premature death in the United States. • >400,000 deaths in the U.S. / year • > 10 million deaths attributed directly to smoking since 1964; about 2 million from lung CA MMWR. Nov ‘98

  3. SMOKING ATTRIBUTABLE HEALTH CARE COSTS: • In 1993, estimated at $50 billion • $27 billion for hospitals • $15.5 billion for physician expenditures • $4.9 billion for nursing homes • $1.8 billion for prescription drugs • $900 million for home health care MMWR ‘94

  4. IN 1995... • 25% of adults in U.S. - current smokers (47 million adults) • Of these, 32 million wanted to quit (68%) • And 17 million (45%) had stopped for > one day MMWR. Dec ‘97

  5. INCIDENCE of SMOKING: NORTH CAROLINA • 26% of those > 18 years smoke; compared with 23% for all states • Gender • 30% of males smoke • 22% of females smoke

  6. CAN PHYSICIANS HELP SOLVE THIS PROBLEM? • >70% smokers see MD yearly • ~70% report wanting to quit • Physician’s advice -- an important motivator

  7. UNFORTUNATELY... • 50% smokers-- report being asked about smoking or urged to quit • Fewer report specific advice on quitting

  8. OBSTACLES TO HELPING PATIENTS QUIT SMOKING • Time constraints • A perceived lack of skills to be effective • Frustration due to low success rates • Belief that smoking cessation is not an important part of professional responsibility

  9. METHODS TO HELP PATIENTS STOP SMOKING: • HEALTH CARE PROVIDER ADVICE AND FOLLOWUP • BEHAVIOR MODIFICATION PROGRAMS • PHARMACOTHERAPY • ALTERNATIVE THERAPIES (e.g.. ACCUPUNCTURE, HYPNOSIS)

  10. NICOTINE REPLACEMENT THERAPY • NICOTINE POLACRILEX “NICOTINE GUM” • NICOTINE PATCH • NICOTINE NASAL SPRAY • NICOTINE INHALER

  11. NICOTINE GUM

  12. NICOTINE GUM • Available in two strengths • 2 mg form was approved by the FDA in 1984 and 4 mg form approved in 1992 • Both strengths became over the counter in April 1996

  13. EFFICACY of NICOTINE GUM • Hjalmarson, et al published RCT on effectiveness of 2 mg nicotine gum • 205 subjects in smoking cessation clinic randomized to nicotine gum or placebo gum • At one year, 29% of nicotine gum subjects were abstinent vs. 16% of the placebo group --JAMA ‘84

  14. HIGHER DOSING OF NICOTINE GUM • In 1995, Herrera N, et al showed “highly dependent” smokers need 4 mg gum • Highly dependent smokers given 4 mg gum or 2 mg gum. * • Lowly dependent smokers given 2 mg gum or placebo.* *(Randomized at “quit phase”) -Chest ‘95

  15. AT 2 YEAR FOLLOW-UP... • Highly dependent group-- Abstinence rates : • 34% for 4 mg and 16% for 2 mg • Lowly dependent group-- Abstinence rates: • 39% for 2 mg and 17 % for placebo • --Chest ‘95

  16. WHAT ABOUT PATIENTS IN A PRIMARY CARE SETTING? • Hughes, et al published RCT performed at 2 family practice clinics in suburbs • 315 smokers assigned 2 mg gum or placebo • Patients shown 13 minute video on gum and instructed to use prn for craving • Brief follow-up visit at 1 to 2 weeks -JAMA ‘89

  17. RESULTS AT ONE YEAR: • 10% of active gum users passed observer and biochemical verification • 7% of placebo users passed observer and biochemical verification • NOT STATISTICALLY SIGNIFICANT • *31 dropouts and 24 noncontacts counted as smokers

  18. PROPER USE OF NICOTINE GUM • NICOTINE GUM IS NOT CHEWED LIKE OTHER CHEWING GUM • COMPRESS with teeth until peppery • “PARK” between the cheek and gum. • REPEAT every minute or so for ~ 30 minutes per dose

  19. EATING AND DRINKING: • Avoid 15 minutes prior to and during use of the gum • Acidic beverages (e.g. coffee, fruit juices) reduce nicotine absorption

  20. DOSING: • Specify a fixed dosing schedule. • > one pack per day begin on 4 mg dose. • At least one piece per hour for 1 to 3 mos. • MAX = 30 pieces of 2 mg gum/day = 20 pieces of 4 mg gum/day

  21. WATCH OUT... • It is possible to become addicted to nicotine gum. • Not recommended for more than 6 months. • Gradual tapering IS recommended

  22. THROAT BURNING DIZZINESS NAUSEA HICCUPS ABDOMINAL PAIN JAW ACHE ADVERSE EFFECTS

  23. NICOTINE PATCH

  24. FIVE FDA-APPROVED TRANSDERMAL PATCHES: Habitrol Nicoderm Nicotrol Nicoderm-CQ Prostep • Available in US in December 1991 • Nicoderm CQ and Nicotrol-- available over the counter • Nicotrol-- delivers nicotine for 16 hours

  25. EFFICACY • Fiore et al performed meta-analysis of RCTS of four weeks or longer that: • Had biochemical confirmation • Subjects not selected on basis of specific diseases (e.g.. coronary artery disease). • - JAMA ‘94

  26. META-ANALYSIS: • Seventeen studies with total 5098 pts • At 6 months...abstinence rates for active patch 22% vs 9% for placebo • Included primary care settings and behavior modification programs. • Combined ODDS RATIOS = 3.0 (6 mo.)

  27. ANALYSIS ALSO FOUND... • 16 hour and 24 hour patch--equally efficacious. • Intensive counseling enhanced clinical success, but patch was effective with minimal adjuvant therapy. • Extending patch treatment > 8 weeks did not increase efficacy. • Weaning patients did not have an added beneficial effect in cessation rate.

  28. REGARDING DOSING... • Available patches = 5 to 22 mg/day of nicotine • Pack per day smoker receives 25 to 40 mg of nicotine/day from cigarettes Will higher patch doses be more effective in heavier smokers?

  29. In 1995, Dale et al looked at percentage of nicotine replacement and smoking cessation • Subjects randomized to 11-, 22-, or 44- mg doses of patch • At one year...higher abstinence rates with the 44 mg patch were not found. • BUT 44 mg patch was safe & superior in relieving withdrawal symptoms. • -JAMA 1995

  30. Current Dosage Recommendations: • > 10 cigarettes per day--use highest available dose • 10 cigarettes per day or fewer -- start with the mid-range dose • Fewer than 5 cigarettes per day probably do not need nicotine replacement.

  31. PROPER USE OF THE NICOTINE PATCH • On the quit date-- apply to a hairless portion of skin after cleansing with soap and water. • Apply new patch daily-- preferably at new site • Use > 8 weeks is not proven beneficial, and weaning may be unnecessary.

  32. SKIN IRRITATION ITCHING NAUSEA INSOMNIA ABNORMAL DREAMS ADVERSE EFFECTS:

  33. NICOTINE NASAL SPRAY

  34. NICOTINE NASAL SPRAY • Available in the United States in 1996 as a prescription product • Designed for rapid delivery of nicotine--mimicking the effects of cigarette smoking

  35. EFFICACY • Sutherland, et al. published RCT examining nicotine nasal spray in a smoking cessation clinic • 227 smokers received 4 weeks of supportive group therapy + active nicotine nasal spray or placebo --Lancet Aug. 92

  36. Main end point was biochemically validated complete abstinence from smoking • At one year...26% of active group abstinent vs. 10% assigned placebo • Greatest advantage in the heaviest smokers • Withdrawal symptoms, craving for cigarettes, and weight gain were all reduced by active spray

  37. WARNING! • Blood nicotine levels achieved are higher and faster than with the patch or gum • Approximately 43% of smokers started on the nicotine nasal spray will continue using for 12 months after smoking cessation

  38. PROPER USE • Instruct the patient on how to “prime the pump” to ready it for use • After priming, patient tilts head back and sprays once in each nostril • Do not intentionally inhale or sniff while spraying! (absorption is in the nasal mucosa not the sinuses)

  39. DOSING... • Each spray delivers 0.5 mg of nicotine (each dose = 1 mg) • Recommend 1 to 2 doses per hour with a maximum of 5 doses per hour (40 mg per day max.) • Treat for 4 to 6 weeks and then wean over an additional 4 to 6 weeks

  40. SIDE EFFECTS • Almost all patients report nasal and throat irritation, sneezing, and watery eyes during week 1 • Symptoms should diminish over the first week of use • If not improving after week 1, consider diseontinuing nasal spray

  41. NICOTINE INHALER

  42. NICOTINE ORAL INHALER • Introduced in mid-1998 • Prescription product • Intended to mimic the smoker’s hand-to-mouth ritual

  43. EFFICACY • A one year RCT conducted by Tonnesen et al. • 286 volunteers recruited through a newspaper ad (each smoked 10+ cigarettes/day) • Subjects randomly assigned to nicotine inhaler or placebo inhaler --JAMA, March 1993

  44. RESULTS... • At one year, smoking abstinence rate in the active inhaler group was 15% vs. 5% in the placebo inhaler group • Minimal levels of advice and support were used in this study • Treatment was well tolerated and no serious adverse effects were reported

  45. NICOTINE DELIVERY • Each cartridge delivers 4 mg of nicotine • About 80 puffs on the inhaler equal nicotine from 8 to 12 puffs on a cigarette • Nicotine absorbed in buccal and pharyngeal mucosa -- not the bronchi • Nicotine plasma concentrations rise more quickly than with gum (slower nasal spray)

  46. DOSING AND USE • Use 6 to 16 cartridges per day • Frequent, continuous puffing over 20 minutes yields the best effects • Recommended duration of treatment is 3 months (max. 6 months)

  47. SIDE EFFECTS • Most common are irritation in the mouth and throat and coughing • Generally improve with use • In the Tonneson study, no subjects discontinued the inhaler secondary to side effects

  48. SMOKING CESSATION CLINICAL PRACTICE GUIDELINES

More Related